New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:49 EDTOMEDOncoMed to present data for Notch1 program
OncoMed Pharmaceuticals will present new data at the upcoming 19th European Hematology Association Congress related to the company's anti-Notch1 clinical-stage program. At the EHA Congress, OncoMed will present the first data for its proprietary Next Generation DNA Sequencing assay developed with MolecularMD to identify Notch1 mutation status in patients with certain hematologic malignancies. OncoMed is currently conducting two separate Phase 1 clinical studies of its Notch1 targeting antibody in patients with certain advanced solid and hematologic tumors, respectively.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 16, 2015
14:33 EDTOMEDOncoMed presents final Phase 1b data for Tarextumab
OncoMed Pharmaceuticals presented final safety, efficacy and biomarker data from the company's Phase 1b "ALPINE" clinical trial of tarextumab in 40 patients with frontline metastatic pancreatic cancer. Tarextumab was generally well tolerated when administered with gemcitabine and Abraxane, with manageable, on-target drug-related toxicities. The Phase 2 dose of tarextumab was determined to be 15 mg/kg every two weeks in combination with the standard-of-care. Among patients evaluable for response using RECIST criteria, 38% achieved partial responses, with an additional 35% achieving stable disease for an overall clinical benefit rate of 73%. Median progression-free survival and overall survival values for the three drug combination of tarextumab-gemcitabine-Abraxane were 5.6 months and 11.6 months, respectively, for all patients treated with the three-drug combination. The data presented included biomarker analyses that showed that among patients whose tumor samples had elevated levels of Notch3 gene expression, trends toward higher response rates and longer survival were noted, as compared to patients with low Notch3 expression. Median PFS and OS for patients with high Notch 3 expression were 6.6 months and 14.6 months, respectively. Given the small sample size and potential imbalances in patient characteristics, these encouraging preliminary efficacy and predictive biomarker observations are being assessed in the ongoing randomized, placebo-controlled, Phase 2 ALPINE trial
January 15, 2015
08:36 EDTOMEDOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
January 12, 2015
08:42 EDTOMEDOncoMed backs view that existing cash, potential milestones may fund operations
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use